KaloBios has announced that Dr V Bryan Lawlis is to join the company’s board of directors.
Dr Lawlis is current president and CEO of Itero Biopharmaceuticals and is a director at several other life sciences companies including Biomarin Pharmaceutical, Geron, and Sutro Biopharmaceuticals.
He has entrepreneurial experience, co-founding Itero in 2006 and contract manufacturing firm Covance Biotechnology Services in 1996.
Other previous roles include CEO of Aradigm Corporation, VP of process sciences at Genetech.
His extensive industry knowledge and drug development experience, especially in the manufacturing of therapeutic proteins and antibodies, will serve KaloBios well as we advance the development of our portfolio of proprietary, patient-targeted, monoclonal antibodies towards commercialisation,” said David Pritchard, president and CEO of KaloBios.
This includes three antibodies in development: one for inflammatory disease, one for lung infection and one for cancer.